These novel agents tested in KMT2Ar and NPM1-m AML have demonstrated meaningful clinical activities with approximately 30% response rates in the relapsed/refractory (R/R) setting and a considerable number showing complete response (CR) with no measurable residual disease (MRD). This evidence concerns the gene NPM1 and acute myeloid leukemia.